Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France.

Date publication

avril 2020

Journal

Digestive diseases and sciences

Auteurs

Membres identifiés du Cancéropôle Est :
Pr THIEFIN Gérard

Tous les auteurs :
Ouzan D, Larrey D, Guyader D, Remy AJ, Riachi G, Heluwaert F, Truchi R, Combis JM, Bailly F, Rosa I, Hézode C, Glorian-Petraud D, Libert O, Ramroth H, Asselah T, Thiefin G, Roulot D, Roche B, Leroy V, Dumortier J, Thabut D, Pol S,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32303953

Résumé

Treatment of hepatitis C virus (HCV) has been dramatically improved with the introduction of direct-acting antiviral agents (DAAs). Universal access to pangenotypic DAAs was provided in France from 2017, expanding the type of patients treated. Real-world studies are important to confirm effectiveness and safety in clinical practice, particularly in vulnerable populations.

Mots clés

France, Hepatitis C, Practice guidelines as topic, Sofosbuvir, Treatment outcome

Référence

Dig. Dis. Sci.. 2020 Apr 18;: